ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag european commission disease medicine neuroscience

2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Mental Map
Abdul-Kareem Ahmed | Nov 13, 2013 | 5 min read
From determining structures to figuring out functions, brain-mapping scientists are applying new technologies to understand the hub of the central nervous system.
Antibody Alternatives
Paul Ko Ferrigno and Jane McLeod | Feb 1, 2016 | 10+ min read
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
Your Body Is Teeming with Weed Receptors
Megan Scudellari | Jul 16, 2017 | 10+ min read
And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.
Senior Scientists Quit Europe
Silvia Sanides | Jun 1, 2003 | 7 min read
©Paul Barton, Corbis Rigid retirement policies are prompting scientists to flee Europe at the height of their professional lives to start second careers in the United States. Many of these researchers are still conducting experiments and are in no mood to slow down. But because nearly all European universities are government run, professors are left little choice when they reach mandatory retirement age, which in most countries is 65 years or even younger. Some scientists leaving for the
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Week in Review: October 5–9
Tracy Vence | Oct 8, 2015 | 2 min read
This year’s Nobel Prizes; toward developing a brown fat-activating drug; certain antioxidants can increase the spread of melanoma in mice; anonymity and post-publication peer review
Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced
Genetics-Based Testing Could Create A Biologic Underclass
Dorothy Nelkin | Nov 26, 1989 | 9 min read
[Editor’s note: Sophisticated biological tests that can uncover latent problems or predict future diseases have been developed over the past few years. Such tests have important clinical applications, but they also have found their way into nonclinical contexts in which they provide unprecedented threats to our traditional concepts of privacy and personal autonomy. So say Dorothy Nelkin and Laurence Tancredi, coauthors of a new book, Dangerous Diagnostics: The Social Power of Biological I

Run a Search

ADVERTISEMENT